Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Avedro Shares Looking Up 35% with Glaukos Merger

Avedro Inc. and Glaukos Corp. announced that the firms' boards of directors have executed a definitive merger agreement. The all-stock deal is expected to close in Q4/19. After the markets closed yesterday afternoon, corneal modeling platform firm Avedro Inc...
Streetwise Reports | August 13, 2019 |

Revolutionizing Mental Health Treatment

(Click to play video.) Cybin Inc. ( NEO: CYBN , NYSE: CYBN , Forum ) is a Toronto-based life sciences company initially focused on psychedelic pharmaceutical therapies supporting research to advance psychedelic therapies centered on improving mental health and...
Featured Submission | August 13, 2021 |

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia

Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/...
Streetwise Reports | November 5, 2019 |

Kiniksa Shares Trade Up 30% on COVID-19 Pneumonia and Hyperinflammation Treatment

Shares of Kiniksa Pharmaceuticals traded higher after the company reported early success in treatment response for mavrilimumab in six patients with severe COVID-19 pneumonia and hyperinflammation. This morning, Hamilton, Bermuda based biopharmaceutical comp...
Streetwise Reports | April 1, 2020 |

Novamind Selected by Merck to Advance Research for Treatment-Resistant Depression

Novamind’s subsidiary, Cedar Clinical Research, to serve as a key clinical research site Independent validation of the expertise and capabilities of Novamind in managing clinical trials Adds to established track record conducting research a...
Featured Submission | March 18, 2021 |

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug

Shares of Kiniksa Pharmaceuticals opened nearly 30% higher today after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis. This morning, Hamilton, Bermuda based biopharmaceutical company ...
Streetwise Reports | November 21, 2019 |

EV predictions show strained metals supply

One of the most prevalent current trends concerning mined commodities is the shift, driven by the effort to reduce our carbon footprint, is towards the electrification of the global transportation system. Electrification is part of the solution to averting further glo...
Richard (Rick) Mills | January 29, 2020 |

Ardelyx's Shares Soar 65% as Tenapanor Phase 3 Study Hits the Mark

Clinical-stage specialized biopharmaceutical company Ardelyx announced positive results today for its phase 3 AMPLIFY study for tenapanor aimed at improving treatment for cardiorenal diseases. This morning clinical-stage biopharmaceutical developer of medicines for th...
Streetwise Reports | September 4, 2019 |

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results

Shares of Relmada Therapeutics have traded wildly today after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100–200% higher today and the stock was halted several times trading due to extreme price volatility. ...
Streetwise Reports | October 16, 2019 |

Savara Shares Double After FDA Grants Breakthrough Therapy Status for aPAP Treatment

Shares of Savara opened nearly 140% higher today after the orphan lung disease company advised that the FDA has granted Breakthrough Therapy designation for the firm's Molgradex for treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). This morning orphan lun...
Streetwise Reports | January 2, 2020 |
1 2 3 4 5 6 7 8 9 10 ...